SpliceBio is pleased to announce the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a g...
Read moreAM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacemen...
Read moreThe MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...
Read moreSparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...
Read moreAdvancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage
Read moreMineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...
Read moreSparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for eye diseases, today announced that it has sold its ex vivo GIRK technology to Tenpoint Therapeutics.
Read moreTagworks Pharmaceuticals BV (“Tagworks”), the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financin...
Read moreCorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials. SPI fund, managed by Bpifrance on behalf of the French Government as part of France 2030, and le...
Read moreMinoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...
Read moreVarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2...
Read moreWith remote patient monitoring of blood pressure through Babyscripts myBloodPressure, MemorialCare providers align with industry guidance from the American College of Obstetricians and Gynecologists (...
Read more